Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The expertise in the characterization of transcriptomics profile in lesional psoriatic skin and on the availability of innovative therapy for these patients.The investigators propose to follow the modification of the skin transcriptomics profile in psoriatic patients during successful Adalimumab biotherapy. Skin transcriptomics profiles of normal skin, psoriatic non lesional skin, and psoriatic lesional skin before and after biotherapy will be compared. The investigators will focus on the modification of the cytokine "signature" in these skin lesions and of some markers of keratinocyte inflammation. The modification of the transcriptomics profile induced by the biotherapy will be correlated to the clinical response Psoriasis Area and Severity Index.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Psoriatic Inflammation Markers Predictive of Response to Adalimumab

NCT03389984

Psoriasis Vulgaris

COMPLETED NA

Adalimumab Biosimilar in Clinical Practice

NCT04808739

Psoriasis

COMPLETED

Chronic Plaque Psoriasis (Ps) Registry

NCT00799877

Chronic Plaque Psoriasis

COMPLETED

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

NCT02581345

Chronic Plaque Psoriasis Psoriasis

COMPLETED PHASE3

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00237887

Psoriasis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Plaque Psoriasis

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adalimumab

Group Type EXPERIMENTAL

HUMIRA 40mg

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HUMIRA 40mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with chronic plaque psoriasis involving at least 10% of body surface area with no previous biotherapy.
* Adalimumab prescribed in usual practice

Exclusion Criteria

* Patients presenting a contraindication to the use of Adalimumab:

hypersensibility in Adalimumab or in one of the excipients.

* Patients presenting an evolutionary tuberculosis or the other severe infections such as sepsis and opportunist infections
* presenting patients one cardiac insufficiencies moderated in severe
* Patients under anakinra or abatacept
* current participation in another study of clinical research

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No